Assessing Market Opportunities in Contract Biologics Manufacturing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Assessing Market Opportunities in Contract Biologics Manufacturing
Strong growth in biopharmaceuticals bodes well for contract manufacturing, but the perils and the promises of pipelines remain.


Pharmaceutical Technology
Volume 33, Issue 5, pp. 56-60

References

1. P. Van Arnum, "Charting API Market Growth and Opportunity." Pharm. Technol. 32 (7), 58–61 (2008).

2. P. Van Arnum, "Global Pharmaceutical Growth Tempered by Lagging US Market," Pharm. Technol. Sourcing and Management , Nov. 2008, http://PharmTech.com/, accessed Apr. 13, 2009.

3. E. Langer, 6th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production , BioPlan Associates (Rockville, MD, Apr. 2009).

4. E. Polastro, "Custom Synthesis and Custom Chemicals," Pharm. Technol . 30 "Outsourcing Resources" supp., 42–66 (2006).

5. P. Van Arnum, "Outlook for Custom Manufacturing Is Mixed," Pharm. Technol. Sourcing and Management , Mar. 2009, http://PharmTech.com/, accessed Apr. 13, 2009.

6. E. Langer, Advances in Biopharmaceutical Technology in China , BioPlan Associates (Rockville, MD, 2007).

7. E. Langer, Top 60 Biopharmaceutical Manufacturers in India , BioPlan Associates (Rockville, MD, Nov. 2008).

8. E. Langer, Advances in Biopharmaceutical Technology in India , BioPlan Associates (Rockville, MD, 2007).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here